Trinity Biotech plc TRIB
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -73.59%
- 1 year
- -79.13%
- Open
- 6.43
- Prev close
- 6.63
- Mkt cap
- 5.09M
- Vol
- 6.70K
- Avg vol
- 19.14K
- EPS
- -60.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.26
- High
- 6.43
- Forward P/E
- -0.87
- Beta
- 1.13
- Short ratio
- 0.43
- Inst. own
- 23.96%
- Dividend
- 0.00
- Ex-div date
- Jun 4, 2015
- 50-d avg
- 1.39
- 200-d avg
- 1.90
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 15, 2024Earnings: -0.43; estimate -0.54; surprise 20.37%
- Jul 24, 2026Split: 1 for 30
Signals (87)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2026 | 2 days ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| RSI: Oversold | Jul 24, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 10, 2026 | 3 months ago |
| RSI: Oversold | Jun 23, 2026 | 4 months ago |
| SMA: Bearish | Jun 16, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 16, 2026 | 6 months ago |
| SMA: Bearish | Apr 15, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| SMA: Bearish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Apr 10, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 20, 2026 | 7 months ago |
| SMA: Bearish | Mar 17, 2026 | 7 months ago |
| SMA: Bullish | Mar 13, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 11, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 10, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 6, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 17, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 6, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 8 months ago |
| SMA: Bearish | Jan 29, 2026 | 9 months ago |
| SMA: Bearish | Jan 29, 2026 | 9 months ago |
| SMA: Bullish | Jan 23, 2026 | 9 months ago |
| SMA: Bullish | Jan 23, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Dec 23, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 23, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 16, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| RSI: Overbought | Dec 9, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 5, 2025 | 11 months ago |
| SMA: Bullish | Nov 28, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 14, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 11, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 28, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 16, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 14, 2025 | 1 year ago |
| SMA: Bearish | Sep 26, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 29, 2025 | 1 year ago |
| RSI: Overbought | Aug 14, 2025 | 1 year ago |
| RSI: Overbought | Aug 12, 2025 | 1 year ago |
| RSI: Overbought | Aug 5, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jul 31, 2025 | 1 year ago |
| SMA: Bearish | Jul 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jul 3, 2025 | 1 year ago |
| SMA: Bearish | Jul 2, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jun 26, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 25, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 12, 2025 | 1 year ago |
| SMA: Bullish | Jun 11, 2025 | 1 year ago |
| SMA: Bearish | May 27, 2025 | 1 year ago |
| MACD: Sell Signal | May 21, 2025 | 1 year ago |
| RSI: Overbought | May 2, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 24, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| SMA: Bearish | Jan 30, 2025 | 1 year ago |
| SMA: Bullish | Jan 28, 2025 | 1 year ago |
| RSI: Overbought | Jan 28, 2025 | 1 year ago |
| RSI: Oversold | Dec 26, 2024 | 1 year ago |
Key statistics
- Market cap
- 24.68M
- Enterprise value
- 347.37M
- Trailing P/E
- 0.00
- Forward P/E
- -0.87
- PEG ratio
- 0.00
- Price / sales
- 0.42
- Price / book
- 0.00
- EPS (TTM)
- -2.25
- Beta
- 1.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -38.01%
- Revenue (TTM)
- 58.65M
- Revenue growth
- 14.00%
- Free cash flow
- -9.93M
- Total cash
- 5.32M
- Total debt
- 93.33M
- Return on equity
- 0.00%
- Shares outstanding
- 27.52M
- Short % of float
- 2.43%
- 50-day average
- 1.39
- 200-day average
- 1.90
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate -0.30.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | -0.54 | -0.43 | +0.11 | +20.37% |
| Aug 14, 2024 | Jun 1, 2024 | -0.65 | -0.55 | +0.10 | +15.38% |
| May 23, 2024 | Mar 1, 2024 | 0.00 | -0.37 | — | — |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | -0.68 | — | — |
| Oct 3, 2023 | Jun 1, 2023 | 0.00 | -1.00 | — | — |
| Jul 6, 2023 | Mar 1, 2023 | 0.00 | -0.80 | — | — |
About Trinity Biotech plc
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Ireland
- Website
- trinitybiotech.com
News
- Head-To-Head Survey: Trinity Biotech (NASDAQ:TRIB) vs. OrthoPediatrics (NASDAQ:KIDS)
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Trinity Biotech's Liquid Cooling Unit Trinovium Enters Contract With Red Team Investments, Owner Of Modular Data Center Technology X-MDC
- Trinity Biotech's Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure
- Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
- Trinity Biotech's Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure
- Trinity Biotech Receives ~$7M Of Additional Investment From Funds Managed By Perceptive Advisors; Regains Compliance With Nasdaq Minimum Bid Price Requirement
- Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
Your note
Sign in to keep a note on TRIB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 79.72% | 1,800,000 | 1.61M | Sep 29, 2024 |
| Hunter Associates Investment Management LLC | 15.93% | 359,810 | 322.75K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 11.08% | 250,153 | 224.39K | Sep 29, 2024 |
| Whitefort Capital Management, LP | 3.63% | 81,902 | 73.47K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.85% | 41,839 | 37.53K | Sep 29, 2024 |
| HRT Financial LP | 1.51% | 34,030 | 30.52K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.22% | 5,077 | 4.55K | Oct 30, 2024 |